Beam Therapeutics Inc (BEAM)
21.38
-0.22
(-1.02%)
USD |
NASDAQ |
Apr 26, 16:00
21.38
0.00 (0.00%)
After-Hours: 20:00
Beam Therapeutics Cash from Financing (Quarterly): 33.71M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 33.71M |
| September 30, 2023 | 36.78M |
| June 30, 2023 | 107.54M |
| March 31, 2023 | 98.42M |
| December 31, 2022 | 32.01M |
| September 30, 2022 | 1.562M |
| June 30, 2022 | 22.34M |
| March 31, 2022 | 55.68M |
| December 31, 2021 | 21.54M |
| September 30, 2021 | 320.89M |
| Date | Value |
|---|---|
| June 30, 2021 | 160.44M |
| March 31, 2021 | 253.27M |
| December 31, 2020 | 129.99M |
| September 30, 2020 | 0.094M |
| June 30, 2020 | -0.779M |
| March 31, 2020 | 193.01M |
| December 31, 2019 | 0.699M |
| September 30, 2019 | 2.692M |
| June 30, 2019 | -0.02M |
| March 31, 2019 | 37.91M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.779M
Minimum
Jun 2020
320.89M
Maximum
Sep 2021
77.36M
Average
33.71M
Median
Dec 2023
Cash from Financing (Quarterly) Benchmarks
| Eli Lilly and Co | 3.545B |
| Moderna Inc | -109.00M |
| Pfizer Inc | 5.442B |
| Editas Medicine Inc | 0.514M |
| Intellia Therapeutics Inc | 106.48M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 135.07M |
| Cash from Investing (Quarterly) | 98.10M |
| Free Cash Flow | -182.93M |
| Free Cash Flow Per Share (Quarterly) | 1.625 |
| Free Cash Flow to Equity (Quarterly) | 131.48M |
| Free Cash Flow to Firm (Quarterly) | 131.48M |
| Free Cash Flow Yield | -11.09% |